Kraig Biocraft Laboratories, Inc. Logo

Kraig Biocraft Laboratories, Inc.

KBLB

(2.0)
Stock Price

0,09 USD

-118.17% ROA

100.44% ROE

-9.4x PER

Market Cap.

40.301.429,00 USD

-35.5% DER

0% Yield

0% NPM

Kraig Biocraft Laboratories, Inc. Stock Analysis

Kraig Biocraft Laboratories, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Kraig Biocraft Laboratories, Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

The stock's ROE exceeds expectations (121.89%), revealing strong profitability and efficient use of shareholders' equity, making it an attractive investment opportunity.

2 PBV

With a remarkably low PBV ratio (-6.91x), the stock offers substantial upside potential at a bargain price.

3 DER

The stock has a minimal amount of debt (-38%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

4 Revenue Growth

With a track record of continuous revenue growth in the last three years, this company offers a promising investment opportunity

5 Net Profit Growth

This company's net profit has consistently grown over the past three years, showcasing a positive financial trend and making it an appealing investment opportunity.

6 ROA

The stock's ROA (-125.71%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

7 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

8 Graham Number

The Graham number calculation reveals that this company's stock price is potentially inflated, implying that it may not be a desirable investment option.

9 Dividend Growth

Potential investors should be aware that the company's dividend growth has shown no upward trend in the past three years, indicating limited potential for increased returns.

10 Dividend

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

11 Buffet Intrinsic Value

The company's stock shows signs of being overvalued (0) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Kraig Biocraft Laboratories, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Kraig Biocraft Laboratories, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Buy
2 MACD Sell
3 RSI Hold
4 Stoch RSI Buy

Kraig Biocraft Laboratories, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Kraig Biocraft Laboratories, Inc. Revenue
Year Revenue Growth
2006 0
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 31.858 100%
2017 97.318 67.26%
2018 401.620 75.77%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Kraig Biocraft Laboratories, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2006 164.913
2007 177.019 6.84%
2008 33.077 -435.17%
2009 69.799 52.61%
2010 141.310 50.61%
2011 250.598 43.61%
2012 465.293 46.14%
2013 489.434 4.93%
2014 439.536 -11.35%
2015 432.008 -1.74%
2016 397.136 -8.78%
2017 258.892 -53.4%
2018 148.069 -74.85%
2019 223.050 33.62%
2020 88.470 -152.12%
2021 197.745 55.26%
2022 176.431 -12.08%
2023 156.516 -12.72%
2023 237.871 34.2%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Kraig Biocraft Laboratories, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2006 370.000
2007 300.000 -23.33%
2008 320.000 6.25%
2009 427.508 25.15%
2010 1.052.522 59.38%
2011 1.046.812 -0.55%
2012 695.113 -50.6%
2013 1.791.035 61.19%
2014 1.394.822 -28.41%
2015 1.622.531 14.03%
2016 2.580.326 37.12%
2017 1.994.421 -29.38%
2018 1.213.498 -64.35%
2019 2.398.817 49.41%
2020 4.445.678 46.04%
2021 2.561.817 -73.54%
2022 1.944.912 -31.72%
2023 991.924 -96.07%
2023 1.579.517 37.2%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Kraig Biocraft Laboratories, Inc. EBITDA
Year EBITDA Growth
2006 -529.667
2007 -472.864 -12.01%
2008 -358.428 -31.93%
2009 -497.307 27.93%
2010 -1.285.979 61.33%
2011 -1.292.040 0.47%
2012 -1.151.631 -12.19%
2013 -2.274.534 49.37%
2014 -1.827.199 -24.48%
2015 -2.039.120 10.39%
2016 -2.928.630 30.37%
2017 -2.135.704 -37.13%
2018 -933.315 -128.83%
2019 -2.584.717 63.89%
2020 -4.556.579 43.28%
2021 -7.436.343 38.73%
2022 -3.204.820 -132.04%
2023 -1.837.780 -74.39%
2023 -2.587.170 28.97%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Kraig Biocraft Laboratories, Inc. Gross Profit
Year Gross Profit Growth
2006 0
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 -15.419 100%
2016 14.884 203.59%
2017 -10.559.902.682 100%
2018 -11.519.598.380 8.33%
2019 -14.793.000.000 22.13%
2020 -13.092.000.000 -12.99%
2021 -3.683.000.000 -255.47%
2022 -28.103 -13105262.42%
2023 0 0%
2023 -27.620 100%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Kraig Biocraft Laboratories, Inc. Net Profit
Year Net Profit Growth
2006 -530.321
2007 -472.986 -12.12%
2008 -360.104 -31.35%
2009 -2.793.143 87.11%
2010 -1.782.888 -56.66%
2011 -1.295.310 -37.64%
2012 -1.202.921 -7.68%
2013 -7.467.685 83.89%
2014 -1.872.987 -298.7%
2015 -2.133.793 12.22%
2016 -3.073.843 30.58%
2017 -2.333.100 -31.75%
2018 -1.168.977 -99.58%
2019 -3.204.202 63.52%
2020 -5.357.901 40.2%
2021 -8.706.222 38.46%
2022 -5.562.685 -56.51%
2023 -2.197.092 -153.18%
2023 -3.029.780 27.48%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Kraig Biocraft Laboratories, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2006 0
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Kraig Biocraft Laboratories, Inc. Free Cashflow
Year Free Cashflow Growth
2006 -10.010
2007 -411.067 97.56%
2008 -96.281 -326.95%
2009 -132.967 27.59%
2010 -222.190 40.16%
2011 -557.270 60.13%
2012 -562.922 1%
2013 -803.627 29.95%
2014 -946.364 15.08%
2015 -1.006.848 6.01%
2016 -1.014.329 0.74%
2017 -760.709 -33.34%
2018 -246.453 -208.66%
2019 -1.188.673 79.27%
2020 -1.254.712 5.26%
2021 -1.897.963 33.89%
2022 -1.892.208 -0.3%
2023 -248.718 -660.78%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Kraig Biocraft Laboratories, Inc. Operating Cashflow
Year Operating Cashflow Growth
2006 -10.010
2007 -411.067 97.56%
2008 -96.281 -326.95%
2009 -132.967 27.59%
2010 -195.450 31.97%
2011 -556.096 64.85%
2012 -562.922 1.21%
2013 -800.154 29.65%
2014 -904.559 11.54%
2015 -967.563 6.51%
2016 -1.011.841 4.38%
2017 -729.542 -38.7%
2018 -235.005 -210.44%
2019 -1.087.881 78.4%
2020 -1.254.712 13.3%
2021 -1.800.809 30.33%
2022 -1.887.187 4.58%
2023 -248.718 -658.77%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Kraig Biocraft Laboratories, Inc. Capital Expenditure
Year Capital Expenditure Growth
2006 0
2007 0 0%
2008 0 0%
2009 0 0%
2010 26.740 100%
2011 1.174 -2177.68%
2012 0 0%
2013 3.473 100%
2014 41.805 91.69%
2015 39.285 -6.41%
2016 2.488 -1478.98%
2017 31.167 92.02%
2018 11.448 -172.25%
2019 100.792 88.64%
2020 0 0%
2021 97.154 100%
2022 5.021 -1834.95%
2023 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Kraig Biocraft Laboratories, Inc. Equity
Year Equity Growth
2006 -257.706
2007 -182.197 -41.44%
2008 -538.301 66.15%
2009 -3.174.777 83.04%
2010 -619.185 -412.73%
2011 -906.495 31.69%
2012 -1.134.416 20.09%
2013 -1.201.402 5.58%
2014 -1.225.682 1.98%
2015 -1.896.936 35.39%
2016 -2.360.813 19.65%
2017 -3.375.806 30.07%
2018 -4.459.223 24.3%
2019 -5.388.058 17.24%
2020 -6.573.564 18.03%
2021 -5.295.875 -24.13%
2022 -3.521.860 -50.37%
2023 -4.998.533 29.54%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Kraig Biocraft Laboratories, Inc. Assets
Year Assets Growth
2006 390
2007 118.318 99.67%
2008 12.660 -834.58%
2009 27.694 54.29%
2010 118.527 76.63%
2011 223.500 46.97%
2012 78.752 -183.8%
2013 311.217 74.7%
2014 539.227 42.28%
2015 304.937 -76.83%
2016 383.659 20.52%
2017 114.499 -235.08%
2018 71.383 -60.4%
2019 750.850 90.49%
2020 1.277.285 41.22%
2021 3.021.912 57.73%
2022 4.570.920 33.89%
2023 3.626.734 -26.03%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Kraig Biocraft Laboratories, Inc. Liabilities
Year Liabilities Growth
2006 258.096
2007 300.515 14.12%
2008 550.961 45.46%
2009 3.202.471 82.8%
2010 737.712 -334.11%
2011 1.129.995 34.72%
2012 1.213.168 6.86%
2013 1.512.619 19.8%
2014 1.764.909 14.29%
2015 2.201.873 19.85%
2016 2.744.472 19.77%
2017 3.490.305 21.37%
2018 4.530.606 22.96%
2019 6.138.908 26.2%
2020 7.850.849 21.81%
2021 8.317.787 5.61%
2022 8.092.780 -2.78%
2023 8.625.267 6.17%

Kraig Biocraft Laboratories, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-0
Price to Earning Ratio
-9.4x
Price To Sales Ratio
0x
POCF Ratio
-29.67
PFCF Ratio
-29.56
Price to Book Ratio
-8.06
EV to Sales
0
EV Over EBITDA
-17.09
EV to Operating CashFlow
-28.84
EV to FreeCashFlow
-28.74
Earnings Yield
-0.11
FreeCashFlow Yield
-0.03
Market Cap
0,04 Bil.
Enterprise Value
0,04 Bil.
Graham Number
0.02
Graham NetNet
-0.01

Income Statement Metrics

Net Income per Share
-0
Income Quality
0.51
ROE
1
Return On Assets
-1.18
Return On Capital Employed
0.39
Net Income per EBT
1.62
EBT Per Ebit
1.37
Ebit per Revenue
0
Effective Tax Rate
-0.66

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0
Operating Profit Margin
0
Pretax Profit Margin
0
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0
Free CashFlow per Share
-0
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
-0.19
Return on Invested Capital
1.03
Return on Tangible Assets
-1.18
Days Sales Outstanding
0
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0
Inventory Turnover
0
Capex per Share
-0

Balance Sheet

Cash per Share
0,00
Book Value per Share
0,00
Tangible Book Value per Share
-0
Shareholders Equity per Share
-0
Interest Debt per Share
0
Debt to Equity
-0.36
Debt to Assets
0.49
Net Debt to EBITDA
0.49
Current Ratio
0.35
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
-0,01 Bil.
Invested Capital
-0.36
Working Capital
-0,01 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
6580
Debt to Market Cap
0.04

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Kraig Biocraft Laboratories, Inc. Dividends
Year Dividends Growth

Kraig Biocraft Laboratories, Inc. Profile

About Kraig Biocraft Laboratories, Inc.

Kraig Biocraft Laboratories, Inc. engages in developing protein-based fibers using recombinant DNA technology for commercial applications in the technical textile and specialty fiber industries in the United States. The company's products are used in military and police applications for ballistic protection; industrial applications, including critical cables and abrasion/impact resistant components; safety equipment; and composite materials for the aero-space industry. Its products are also used in various markets, such as medical textiles, geotextiles, defense and military textiles, safe and protective clothing, filtration textiles, composites with textile structure, and functional and sportive textiles, as well as textiles used in buildings and transportation. The company was incorporated in 2006 and is headquartered in Ann Arbor, Michigan.

CEO
Mr. Kim Kraig Thompson
Employee
36
Address
2723 South State Street
Ann Arbor, 48104

Kraig Biocraft Laboratories, Inc. Executives & BODs

Kraig Biocraft Laboratories, Inc. Executives & BODs
# Name Age
1 Mr. Jonathan R. Rice
Chief Operating Officer
70
2 Dr. Trevor L. Kane
Chief Scientist & Member of Scientific Advisory Board
70
3 Mr. Kenneth Le
Director of Government Relations & President of Prodigy Textiles
70
4 Mr. Kim Kraig Thompson
Founder, Chairman, Chief Executive Officer, President, Chief Financial Officer & Corporate Secretary
70

Kraig Biocraft Laboratories, Inc. Competitors